Meta-analysis of repaglinide in treatment of obese and non-obese patients with type 2 diabetes

WEI Jin-fei; ZHOU Liang; WANG Ming-mei; WANG Xin-hui; ZHANG Xin; WANG Xiao-qing

Abstract：Objective: To evaluate the efifcacy and safety of repaglinide in the treatment of obese and non-obese patients with type 2 diabetes (T2DM).Methods: Databases from PubMed, EMbase, The Cochrane Library, Wanfang, VIP and CNKI were searched to extract the studies about repaglinide in the treatment of obese and non-obese patients with T2DM. After the screening, according to the inclusion and exclusion criteria, the data extracting and quality evaluating were performed by 2 researchers, and then meta-analysis was performed using RevMan 5.2 software.Results:A total of 6 controlled clinical trials (CCT) including 789 patients involved in the study. The results of meta-analysis showed that the effects of repaglinide in lowering HbAlc [MD = – 0.35, 95%CI(– 0.54, – 0.15),P = 0.0005] and BMI [MD = – 3.33, 95%CI(– 4.12, – 2.54),P < 0.00001] in obese group were better than those in the non-obese group. However, repaglinide showed similar effects of lowering FPG [MD = – 0.26, 95%CI(– 0.76, 0.24),P = 0.31] and 2 hPG [MD = – 0.21, 95%CI(– 1.18, 0.76),P = 0.68] in both obese group and non-obese group. The risk of ADR in non-obese group was higher than that in obese group [RR = 0.27, 95%CI(0.10, 0.71),P = 0.008]. The results of heterogeneity were as follows: HbA1c [P = 0.60, (P > 0.10),I2 = 0%)], FPG [P = 0.01 (P < 0.10),I2 = 66%], 2 hPG [P = 0.001 (P < 0.10),I2 = 75%], BMI [P = 0.62 (P >0.10),I2 = 0%] and ADR [P = 0.44 (P > 0.10),I2 = 0%].Conclusion: The effect of repaglinide in the treatment of obese patients with T2DM was more effective than that in non-obese patients with T2DM, while the risk of ADR was lower.